ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On July31, 2017, ZIOPHARM Oncology, Inc., or the Company, issued a press release announcing its financial condition and results of operations for the three months ended June30, 2017.A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
This information, including the information contained in the press release furnished as Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Company’s filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.
|Item 2.02||Financial Statements and Exhibits|
|99.1||Press Release of ZIOPHARM Oncology, Inc. dated July 31, 2017|
ZIOPHARM ONCOLOGY INC ExhibitEX-99.1 2 d433078dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities – Company to Host Conference Call Today at 4:30 p.m. ET – BOSTON,…To view the full exhibit click
About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.